Inflammation-nature's way to efficiently respond to all types of challenges: Implications for understanding and managing "the epidemic" of chronic diseases

Frontiers in Medicine

Volumn 5, Issue NOV, 2018, Pages

  Bennett, Jeanette M ^a   Reeves, Glenn ^b   Billman, George E ^c   Sturmberg, Joachim P ^d,e  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e International Society for Systems and Complexity Sciences for Health   (United States)

Author keywords

Anti inflammatory lifestyle; Chronic disease; Clinical care; Complex adaptive systems; Inflammation; Interdisciplinary; Stress

Indexed keywords

EID: 85060648877     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2018.00316     Document Type: Article

References (257)

1. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. (2001) 15:7-24. doi: 10.1006/brbi.2000.0613
2. Maier SF, Watkins LR. Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev. (1998) 105:83-107
3. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol. (2006) 172:38-58. doi: 10.1016/j.jneuroim.2005.10.017
4. Han R. Plasma lipoproteins are important components of the immune system. Microbiol Immunol. (2010) 54:246-53. doi: 10.1111/j.1348-0421.2010.00203.x
5. Shedlock DJ, Shen H. Requirement for CD4 T Cell help in generating functional CD8 T cell memory. Sci Just. (2003) 300:337-9. doi: 10.1126/science.1082305
6. Murphy K, Reiner S. The lineage decisions of helper T cells. Nat Rev Immunol. (2002) 2:933-44. doi: 10.1038/nri954
7. Amsen D, Spilanakis C, Flavell R. How are TH1 and TH2 cells made? Curr Opin Immunol. (2009) 21:153-60. doi: 10.1016/j.coi.2009.03.010
8. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. (2010) 11:373-84. doi: 10.1038/ni.1863
9. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. (2007) 7:179-90. doi: 10.1038/nri2038
10. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell (2010) 140:805-20. doi: 10.1016/j.cell.2010.01.022
11. Kuric E, Ruscher K. Dynamics of major histocompatibility complex class II-positive cells in the postischemic brain-influence of levodopa treatment. J Neuroinflamm. (2014) 11:145. doi: 10.1186/s12974-014-0145-z
12. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. (1997) 29:1129-88
13. Parke DV, Parke AL. Chemical-induced inflammation and inflammatory diseases. Int J Occup Med Environ Health (1996) 9:211-7
14. Lamas B, Natividad JM, Sokol H. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunol. (2018) 2018:1. doi: 10.1038/s41385-018-0019-2
15. Mandal PK. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Compar Physiol B. (2005) 175:221-30. doi: 10.1007/s00360-005-0483-3
16. Petersen A, Pedersen B. The role of IL-6 in mediating the anti inflammatory. J Physiol Pharmacol. (2006) 57(Suppl. 10):43-51
17. Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters. Brain Behav Immun. (2018) 70:61-75. doi: 10.1016/j.bbi.2018.02.013
18. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci. (2012) 1261:55-63. doi: 10.1111/j.1749-6632.2012.06633.x
19. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol. (2006) 6:318-28. doi: 10.1038/nri1810
20. Goda S, Inoue H, Domae E, Kagawa M, Hosoyama Y, Matsumoto N, et al. Matrix metalloproteinase-1 produced by human CXCL8-activated NK cells. J Oral Tissue Eng. (2013) 11:163-71. doi: 10.2353/ajpath.2006.050676
21. Toft-Hansen H, Buist R, Sun X-J, Schellenberg A, Peeling J, Owens T. Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system. J Immunol. (2006) 177:7242-9. doi: 10.4049/jimmunol.177.10.7242
22. Dantzer R. Innate immunity at the forefront of psychoneuroimmunology. Brain Behav Immun. (2004) 18:1-6. doi: 10.1016/j.bbi.2003.09.008
23. Godbout JP, Johnson RW. Age and neuroinflammation: a lifetime of psychoneuroimmune consequences. Immunol Allerg Clin N A. (2009) 29:321-37. doi: 10.1016/j.ncl.2006.03.010
24. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. JAMA (1992) 267:1244-52. doi: 10.1001/jama.1992.03480090092034
25. Sapolsky R, Krey L, McEwen B. Glucocorticoid-sensitive hippocampal neurons are involved in terminating the adrenocortical stress response. Proc Natl Acad Sci USA. (1984) 81:6174. doi: 10.1073/pnas.81.19.6174
26. Da Silva JAP. Sex hormones and glucocorticoids: Interactions with the immune system. In: Cutolo M, Masi AT, Bijlsma JWJ, Chikanza IC, Bradlow HL, Castagnetta L, editors. Neuroendocrine Immune Basis of the Rheumatic Diseases. Annals of the New York Academy of Sciences. 876. New York, NY: New York Acad Sciences (1999). p. 102-18
27. Kajantie E, Phillips D. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology (2006) 31:151-78. doi: 10.1016/j.psyneuen.2005.07.002
28. Taylor SE, Gonzaga GC, Klein LC, Hu P, Greendale GA, Seeman TE. Relation of oxytocin to psychological stress responses and hypothalamic-pituitary-adrenocortical axis activity in older women. Psychosom Med. (2006) 68:238-45. doi: 10.1097/01.psy.0000203242.95990.74
29. Bennett JM, Gillie BL, Lindgren ME, Fagundes CP, Kiecolt-Glaser JK. Inflammation through a psychoneuroimmunological lens. In: Sturmberg, JP, Martin, CM, editors. Handbook of Systems and Complexity in Health. New York, NY:Springer (2013). p. 279-99
30. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. (1998) 94:557-72
31. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. (1996) 10:81-90. doi: 10.1046/j.1365-2036.1996.22164025.x
32. Webster JC, Cidlowski JA. Downregulation of the glucocorticoid receptor. a mechanism for physiological adaptation to hormones. Ann N Y Acad Sci. (1994) 746:216-20
33. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Ann Rev Immunol. (2002) 20:125-63. doi: 10.1146/annurev.immunol.20.082401.104914
34. Sapolsky R, Krey L, McEwen B. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. (1985) 5:1222. doi: 10.1523/JNEUROSCI.05-05-01222.1985
35. Miller G, Cohen S, Ritchey A. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. Health Psychol. (2002) 21:531-41. doi: 10.1037/0278-6133.21.6.531
36. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA. (2003) 100:1920-5. doi: 10.1073/pnas.0438019100
37. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Eng J Med. (1997) 336:1066-71. doi: 10.1056/NEJM199704103361506
38. Baldwin AS. The NF-kappa B and I kappa B proteins: New discoveries and insights. Ann Rev Immunol. (1996) 14:649-83
39. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. (2002) 16:622-53. doi: 10.1016/S0889-1591(02)00021-1
40. Watkins LR, Goehler LE, Relton JK, Tartaglia N, Silbert L, Martin D, et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy:evidence for vagal mediation of immune-brain communication. Neurosci Lett. (1995) 183:27-31. doi: 10.1016/0304-3940(94)11105-R
41. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature (2000) 405:458-62. doi: 10.1038/35013070
42. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immun. (2005) 19:493-9. doi: 10.1016/j.bbi.2005.03.015
43. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. (2007) 117:289-96. doi: 10.1172/JCI30555
44. Gallowitsch-Puerta M, Tracey KJ. Immunologic role of the cholinergic anti-inflammatory pathway and the nicotinic acetylcholine alpha 7 receptor. In: Steinman RM, editor. Human Immunology: Patient-Based Research. Annals of the New York Academy of Sciences. 1062. New York, NY: New York Acad Sciences (2005). p. 209-19
45. Thayer JF. Vagal tone and the inflammatory reflex. Clevel Clin J Med. (2009) 76(Suppl 2):S23-6. doi: 10.3949/ccjm.76.s2.05
46. Porges S. The polyvagal theory: phylogenetic substrates of a social nervous system. Int J Psychophysiol. (2001) 42:123-46. doi: 10.1016/S0167-8760(01)00162-3
47. Thayer JF, Lane RD. A model of neurovisceral integration in emotion regulation and dysregulation. J Affect Disord. (2000) 61:201-16. doi: 10.1016/S0165-0327(00)00338-4
48. Drury RL. The evolution of family medicine: a focused review. Arch Commun Fam Med. (2018) 1:51-4
49. Dalli J, Serhan CN. Immunoresolvents signaling molecules at intersection between the brain and immune system. Curr Opin Immunol. (2018) 50:48-54. doi: 10.1016/j.coi.2017.10.007
50. Serhan CN. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J. (2017) 31:1273-88. doi: 10.1096/fj.201601222R
51. Chiurchiù V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog Neurobiol. (2017) 160:82-100. doi: 10.1016/j.pneurobio.2017.10.007
52. Chiurchiù V, Orlacchio A, Maccarrone M. Is modulation of oxidative stress an answer? The state of the art of redox therapeutic actions in neurodegenerative diseases. Oxidat Med Cell long. (2016) 2016:7909380. doi: 10.1155/2016/7909380
53. Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. (2017) 58:1-11. doi: 10.1016/j.mam.2017.03.001
54. Chiurchiù V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. (2018) 9:38. doi: 10.3389/fimmu.2018.00038
55. Cole SW. Social regulation of human gene expression: mechanisms and implications for public health. Am J Public Health (2013) 103:S84-S92. doi: 10.2105/AJPH.2012.301183
56. Bierhaus A, Humpert PM, Nawroth PP. NF-kappa B as a molecular link between psychosocial stress and organ dysfunction. Pediatr Nephrol. (2004) 19:1189-91. doi: 10.1007/s00467-004-1603-0
57. Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabási A-L. The human disease network. Proc Natl Acad Sci. (2007) 104:8685-90. doi: 10.1073/pnas.0701361104
58. Goh K-I, Choi I-G. Exploring the human diseasome: the human disease network. Briefi Funct Genom. (2012) 11:533-42. doi: 10.1093/bfgp/els032
59. Sturmberg JP, Bennett JM, Martin CM, Picard M. 'Multimorbidity'as the manifestation of network disturbances. J Eval Clin Pract. (2017) 23:199-208. doi: 10.1111/jep.12587
60. Australian Institute of Health and Welfare. Young Australians: Their Health and Wellbeing. Canberra, ACT: Australian Institute of Health and Welfare (2007)
61. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature (2008) 454:445-54. doi: 10.1038/nature07204
62. Holloway JI. Genetics and epigenetics of allergic diseases and asthma. In: Adkinson Jr. N, Bochner B, Burks A, Busse W, Holgate S, Lemanske R, O'Hehir R, editors. Middleton's Allergy: Principles and Practice. 8th ed. Philadelphia, PA: Elsevier (2014). p. 343-63
63. Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol. (2015) 15:57. doi: 10.1038/nri3786
64. Segura E, Villadangos JA. Antigen presentation by dendritic cells in vivo. Curr Opin Immunol. (2009) 21:105-10. doi: 10.1016/j.coi.2009.03.011
65. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol. (2003) 3:721-32. doi: 10.1038/nri1181
66. Bousso P. T-cell activation by dendritic cells in the lymph node: lessons from the movies. Nat Rev Immunol. (2008) 8:675-84. doi: 10.1038/nri2379
67. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity (2009) 31:425-37. doi: 10.1016/j.immuni.2009.08.014
68. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. (1997) 84:223-43. doi: 10.1006/clin.1997.4412
69. Schatz DG. V(D)J recombination. Immunol Rev. (2004) 200:5-11. doi: 10.1111/j.0105-2896.2004.00173.x
70. Goodnow CC, Sprent J, de St Groth BF, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 435:590-7. doi: 10.1038/nature03724
71. Bour-Jordan H, Bluestone JA. CD28 Function: a balance of costimulatory and regulatory signals. J Clin Immunol. (2002) 22:1-7. doi: 10.1023/A:1014256417651
72. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol. (2003) 3:169-76. doi: 10.1038/nri1004
73. Kyewski B, Klein L. A central role for central tolerance. Ann Rev Immunol. (2006) 24:571-606. doi: 10.1146/annurev.immunol.23.021704.115601
74. Mathis D, Benoist C. Aire. Ann Rev Immunol. (2009) 27:287-312. doi: 10.1146/annurev.immunol.25.022106.141532
75. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. (2005) 6:345-52. doi: 10.1038/ni1178
76. Cornall RJ, Goodnow CC, Cyster JG. The regulation of self-reactive B cells. Curr Opin Immunol. (1995) 7:804-11. doi: 10.1016/0952-7915(95)80052-2
77. Silverstein AM, Rose NR. There is only one immune system! The view from immunopathology. Semin Immunol. (2000) 12:173-8. doi: 10.1006/smim.2000.0228
78. Janeway CA. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Tod. (1992) 13:11-6
79. Sinha A, Lopez M, McDevitt H. Autoimmune diseases: the failure of self tolerance. Science (1990) 248:1380-8. doi: 10.1126/science.1972595
80. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest. (2006) 116:1713-22. doi: 10.1172/JCI25112
81. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. (2006) 19:80-94. doi: 10.1128/CMR.19.1.80-94.2006
82. Fernando MMA, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. (2008) 4:e1000024. doi: 10.1371/journal.pgen.1000024
83. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature (1994) 372:100-3. doi: 10.1038/372100a0
84. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med. (2015) 21:730-8. doi: 10.1038/nm.3897
85. Getz GS. Thematic review series: the immune system and atherogenesis. Immune function in atherogenesis. J Lipid Res. (2005) 46:1-10. doi: 10.1194/jlr.R400013-JLR200
86. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. (2011) 12:204-12. doi: 10.1038/ni.2001
87. Birck MM, Pesonen E, Odermarsky M, Hansen AK, Persson K, Frikke-Schmidt H, et al. Infection-induced coronary dysfunction and systemic inflammation in piglets are dampened in hypercholesterolemic milieu. Am J Physiol. (2011) 300:H1595-H601. doi: 10.1152/ajpheart.01253.2010
88. Wei C-Y, Huang K-C, Chou Y-H, Hsieh P-F, Lin K-H, Lin W-W. The role of rho-associated kinase in differential regulation by statins of interleukin-1β-and lipopolysaccharide-mediated nuclear factor κb activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells. Mol Pharmacol. (2006) 69:960-7. doi: 10.1124/mol.105.017368
89. Billman GE. Cardiac autonomic neural remodeling and susceptibility to sudden cardiac death: effect of endurance exercise training. Am J Physiol. (2009) 297:H1171-93. doi: 10.1152/ajpheart.00534.2009
90. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH, et al. Associations of elevated Interleukin-6 and C-Reactive protein levels with mortality in the elderly** Am J Med. (1999) 106:506-12
91. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation (2002) 105:2595-9. doi: 10.1161/01.CIR.0000017493.03108.1C
92. Korngold EC, Januzzi JL, Gantzer ML, Moorthy MV, Cook NR, Albert CM. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation (2009) 119:2868-76. doi: 10.1161/CIRCULATIONAHA.108.832576
93. Empana J-P, Jouven X, Canouï-Poitrine F, Luc G, Tafflet M, Haas B, et al. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in european middle-aged men: the PRIME study. Arterioscl Thromb Vasc Biol. (2010) 30:2047-52. doi: 10.1161/ATVBAHA.110.208785
94. Mountantonakis S, Deo R. Biomarkers in atrial fibrillation, ventricular arrhythmias, and sudden cardiac death. Cardiovasc Therap. (2012) 30:e74-e80. doi: 10.1111/j.1755-5922.2010.00238.x
95. Hussein AA, Gottdiener JS, Bartz TM, Sotoodehnia N, DeFilippi C, See V, et al. Inflammation and sudden cardiac death in a community-based population of older adults: The cardiovascular health study. Heart Rhythm (2013) 10:1425-32. doi: 10.1016/j.hrthm.2013.07.004
96. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med. (2011) 17:556-63. doi: 10.1016/j.molmed.2011.05.007
97. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. (2012) 60:2263-70. doi: 10.1016/j.jacc.2012.04.063
98. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation (1997) 96:1180-4. doi: 10.1161/01.CIR.96.4.1180
99. Granier M, Massin F, Pasquie J-L. Pro-and anti-arrhythmic effects of anti-inflammatory drugs. Anti-Inflamm Anti-Allerg Agents Med Chem. (2013) 12:83-93. doi: 10.2174/1871523011312010010
100. Apostolopoulos V, Courten MP, Stojanovska L, Blatch GL, Tangalakis K, Courten B. The complex immunological and inflammatory network of adipose tissue in obesity. Mol Nutr Food Res. (2015) 60:43-57. doi: 10.1002/mnfr.201500272
101. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. (2004) 89:2548-56. doi: 10.5114/aoms.2013.33181
102. Kargi AY, Iacobellis G. Adipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applications. Int J Endocrinol. (2014) 2014:614074. doi: 10.1155/2014/614074
103. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. J Am Med Assoc. (1999) 282:2131-5. doi: 10.1001/jama.282.22.2131
104. Fransson EI, Batty GD, Tabak AG, Brunner EJ, Kumari M, Shipley MJ, et al. Association between change in body composition and change in inflammatory markers: an 11-year follow-up in the Whitehall II Study. J Clin Endocrinol Metab. (2010) 95:5370-4. doi: 10.1210/jc.2010-0730
105. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. (1997) 82:4196-200
106. McInnis CM, Thoma MV, Gianferante D, Hanlin L, Chen X, Breines JG, et al. Measures of adiposity predict interleukin-6 responses to repeated psychosocial stress. Brain Behav Immun. (2014) 42:33-40. doi: 10.1016/j.bbi.2014.07.018
107. Brydon L, Wright CE, O'Donnell K, Zachary I, Wardle J, Steptoe A. Stress-induced cytokine responses and central adiposity in young women. Int J Obesity (2008) 32:443-50. doi: 10.1038/sj.ijo.0803767
108. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. (2001) 60:349-56. doi: 10.1079/PNS2001110
109. Sapolsky R, Rivier C, Yamamoto G. Interleukin-1 stimulates the secretion of hypothalmic corticotropin-releasing factor. Science (1987) 238:522-6. doi: 10.1126/science.2821621
110. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, Loeser RF, et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr. (2004) 79:544-51. doi: 10.1093/ajcn/79.4.544
111. Bruun JM, Stallknecht B, Helge JW, Richelsen B. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol. (2007) 157:465-71. doi: 10.1530/EJE-07-0206
112. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA (2003) 289:1799-804. doi: 10.1001/jama.289.14.1799
113. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res. (2003) 11:1055-64. doi: 10.1038/oby.2003.145
114. Hamer M, Steptoe A. Prospective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and women. Am J Clin Nutr. (2009) 89:85-9. doi: 10.3945/ajcn.2008.26779
115. Reaven GM. Role of insulin resistance in human disease. Diabetes (1988) 37:1595-607. doi: 10.2337/diab.37.12.1595
116. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in wealthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction-A potential role for cytokines originating from adipose tissue? Arteriosc Thromb Vasc Biol. (1999) 19:972-8
117. Pradhan A, Manson J, Rifai N, Buring J, Ridker P. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 286:327-34. doi: 10.1001/jama.286.3.327
118. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. (2003) 112:1821. doi: 10.1172/JCI200319451
119. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. (2001) 280:E745-51. doi: 10.1152/ajpendo.2001.280.5.E745
120. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. (2003) 98:2751-6. doi: 10.1111/j.1572-0241.2003.08728.x
121. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. (2006) 24:83-6
122. Bastard J-P, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. (2006) 17:4-12
123. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, et al. FEtuin-a and incident diabetes mellitus in older persons. JAMA (2008) 300:182-8. doi: 10.1001/jama.300.2.182
124. Stefan N, Fritsche A, Weikert C, Boeing H, Joost H-G, Häring H-U, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes (2008) 57:2762-7. doi: 10.2337/db08-0538
125. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Kröber SM, et al. a2-Heremans-schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care (2006) 29:853-7. doi: 10.2337/diacare.29.04.06.dc05-1938
126. Mathews ST, Chellam N, Srinivas PR, Cintron VJ, Leon MA, Goustin AS, et al. a 2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol. (2000) 164:87-98. doi: 10.1016/S0303-7207(00)00237-9
127. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. (2012) 18:1279-85. doi: 10.1038/nm.2851
128. Bulcão C, Ribeiro-Filho FF, Sañudo A, Ferreira SGR. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs (2007) 7:219-24. doi: 10.2165/00129784-200707030-00007
129. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. (2007) 153:445. e1-e6. doi: 10.1016/j.ahj.2006.11.005
130. Association AP. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition: DSM-5. Arlington, VA: American Psychiatric Association (2013)
131. Sternberg EM. Emotions and disease: From balance of humors to balance of molecules. Nat Med. (1997) 3:264-267
132. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, et al. Cytokine-induced sickness behavior. Brain Behav Immun. (2003) 17(Suppl 1):S112-8. doi: 10.1016/S0889-1591(02)00077-6
133. Raison CL, Miller AH. Is Depression an inflammatory disorder? Curr Psychiatry Rep. (2011) 13:467-75. doi: 10.1007/s11920-011-0232-0
134. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry (1998) 55:580-92. doi: 10.1001/archpsyc.55.7.580
135. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Instit Monogr. (2004) 2004:57-71. doi: 10.1093/jncimonographs/lgh014
136. Bremmer MA, Beekman AT, Deeg DJ, Penninx BW, Dik MG, Hack CE, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. (2008) 106:249-55. doi: 10.1016/j.jad.2007.07.002
137. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. (2004) 164:1010-4. doi: 10.1001/archinte.164.9.1010
138. Glaser R, Robles T, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses following influenza vaccination in older adults. Arch Gen Psychiatry (2003) 60:1009-14. doi: 10.1001/archpsyc.60.10.1009
139. Pace TWW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 163:1630-2. doi: 10.1176/ajp.2006.163.9.1630
140. Miller GE, Freedland KE, Carney RM. Depressive symptoms and the regulation of proinflammatory cytokine expression in patients with coronary heart disease's. J Psychosom Res. (2005) 59:231-6. doi: 10.1016/j.jpsychores.2005.06.004
141. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry (2001) 58:445-52. doi: 10.1001/archpsyc.58.5.445
142. Bryclon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biological Psychiatry (2008) 63:1022-9. doi: 10.1016/j.biopsych.2007.12.007
143. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. (2008) 85:1-74. doi: 10.1016/j.pneurobio.2008.01.004
144. Bennett JM, Sturmberg JP. Depression: Not Just a Top-Down Phenomenon. The Value of Systems and Complexity Sciences for Healthcare. Charm: Springer (2016)
145. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: Depression fans the flames and feasts on the heat. Am J Psychiatry (2015) 172:1075-91. doi: 10.1176/appi.ajp.2015.15020152
146. Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O'Neil A, et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. (2013) 11:74. doi: 10.1186/1741-7015-11-74
147. Lindqvist D, Epel ES, Mellon SH, Penninx BW, Révész D, Verhoeven JE, et al. Psychiatric disorders and leukocyte telomere length: underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev. (2015) 55:333-64. doi: 10.1016/j.neubiorev.2015.05.007
148. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J-P, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. (2011) 7:33-42. doi: 10.1038/nrrheum.2010.196
149. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthr Cart. (2013) 21:16-21. doi: 10.1016/j.joca.2012.11.012
150. Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol. (2013) 146:185-96. doi: 10.1016/j.clim.2012.12.011
151. Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology (2005) 44:7-16. doi: 10.1093/rheumatology/keh344
152. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone (2012) 51:249-57. doi: 10.1016/j.bone.2012.02.012
153. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, et al. Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev. (2007) 128:83-91. doi: 10.1016/j.mad.2006.11.015
154. Goldberg EL, Dixit VD. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev. (2015) 265:63-74. doi: 10.1111/imr.12295
155. Tosato M, Zamboni V, Ferrini A, Cesari M. The aging process and potential interventions to extend life expectancy. Clin Interv Aging (2007) 2:401-12
156. Woods JA, Wilund KR, Martin SA, Kistler BM. Exercise, Inflammation and Aging. Aging Dis. (2012) 3:130-40
157. Freund A, Orjalo AV, Desprez P-Y, Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med. (2010) 16:238-46. doi: 10.1016/j.molmed.2010.03.003
158. Bruunsgaard H. The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality. Danish Med Bull. (2006) 53:285-309
159. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol Series A (2006) 61:575-84. doi: 10.1093/gerona/61.6.575
160. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. (2007) 128:92-105. doi: 10.1016/j.mad.2006.11.016
161. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol. (2009) 21:418-24. doi: 10.1016/j.coi.2009.05.023
162. Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J. (2005) 19:1329-31. doi: 10.1096/fj.05-3776fje
163. Dilger RN, Johnson RW. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukocyte Biol. (2008) 84:932-9. doi: 10.1189/jlb.0208108
164. Cunningham C, MacLullich AMJ. At the extreme end of the psychoneuroimmunological spectrum: Delirium as a maladaptive sickness behaviour response. Brain Behav Immun. (2013) 28:1-13. doi: 10.1016/j.bbi.2012.07.012
165. Heng HH. Heterogeneity-mediated cellular adaptation and its trade-off: searching for the general principles of diseases. J Eval Clin Pract. (2017) 23:233-7. doi: 10.1111/jep.12598
166. Rohleder N. Translating biobehavioral research advances into improvements in health care-a "network of networks" approach to multimorbidity. J Eval Clin Pract. (2017) 23:230-2. doi: 10.1111/jep.12657
167. Aron DC. Multimorbidity: an endocrinologist looks at multi-level network disruption and at what gets diabetes? J Eval Clin Pract. (2017) 23:225-9. doi: 10.1111/jep.12600
168. Bircher J, Hahn EG. "Multimorbidity" as the manifestation of network disturbances. From nosology to the Meikirch model. J Eval Clin Pract. (2017) 23:222-4. doi: 10.1111/jep.12633
169. DeHaven MJ. Multimorbidity, chronic disease, and community health science. J Eval Clin Pract. (2017) 23:219-21. doi: 10.1111/jep.12632
170. Melis RJF, Gijzel SMW, Olde Rikkert MGM. Moving beyond multimorbidity as a simple count of diseases. J Eval Clin Pract. (2017) 23:216-8. doi: 10.1111/jep.12693
171. Marcum JA. Multimorbidity, P4 medicine and holism. J Eval Clin Pract. (2017) 23:213-5. doi: 10.1111/jep.12588
172. Walker C, Peterson CL. Multimorbidity: a sociological perspective of systems. J Eval Clin Pract. (2017) 23:209-12. doi: 10.1111/jep.12599
173. Miles A, Asbridge JE. Multimorbidity-A manifestation of network disturbances? How to investigate? How to treat? J Eval Clin Pract. (2017) 23:193-8. doi: 10.1111/jep.12723
174. Sedivy R. 200 Jahre Rokitansky-sein Vermächtnis für die heutige Pathologie. Wiener Klinische Wochenschrift (2004) 116:779-87. doi: 10.1007/s00508-004-0272-0
175. Steurer J, Bachmann L, Miettinen O. Etiology in a taxonomy of illnesses. Eur J Epidemiol. (2006) 21:85-9. doi: 10.1007/s10654-005-5925-4
176. Sturmberg JP, Martin CM. Diagnosis-the limiting focus of taxonomy. J Eval Clin Pract. (2016) 22:103-11. doi: 10.1111/jep.12113
177. Loscalzo J, Kohane I, Barabasi A-L. Human disease classification in the postgenomic era: A complex systems approach to human pathobiology. Mol Syst Biol. (2007) 3:124. doi: 10.1038/msb4100163
178. Sturmberg JP. The personal nature of health. J Eval Clin Pract. (2009) 15:766-9. doi: 10.1111/j.1365-2753.2009.01225.x
179. Sturmberg JP. Health: a personal complex-adaptive state. In: Sturmberg JP, Martin CM, editors. Handbook of Systems and Complexity in Health. New York, NY: Springer (2013). p. 231-42
180. White K, Williams F, Greenberg B. The Ecology of Medical Care. N Eng J Med. (1961) 265:885-92. doi: 10.1056/NEJM196111022651805
181. Green L, Fryer G, Yawn B, Lanier D, Dovey S. The ecology of medical care revisited. N Eng J Med. (2001) 344:2021-5. doi: 10.1056/NEJM200106283442611
182. Johansen ME, Kircher SM, Huerta TR. Reexamining the ecology of medical care. N Eng J Med. (2016) 374:495-6. doi: 10.1056/NEJMc1506109
183. Engel GL. The clinical application of the biopsychosocial model. Am J Psychiatry (1980) 137:535-44. doi: 10.1176/ajp.137.5.535
184. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. (2003) 92:17K-22K. doi: 10.1016/S0002-9149(03)00774-4
185. Morra E, Cesana C, Klersy C, Barbarano L, Varettoni M, Cavanna L, et al. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia (2004) 18:1512. doi: 10.1038/sj.leu.2403442
186. Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol. (2010) 125(2 Suppl 2):S297-305. doi: 10.1016/j.jaci.2009.08.043
187. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. (1999) 106:506-12. doi: 10.1016/S0002-9343(99)00066-2
188. Bauer J, Hohagen F, Ebert T, Timmer J, Ganter U, Krieger S, et al. Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clin Invest. (1994) 72:315. doi: 10.1007/BF00180048
189. Moldofsky H, Lue FA, Eisen J, Keystone E, Gorczynski RM. The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med. (1986) 48:309-18. doi: 10.1097/00006842-198605000-00001
190. Bennett JM, Glaser R, Malarkey WB, Beversdorf DQ, Peng J, Kiecolt-Glaser JK. Inflammation and reactivation of latent herpesviruses in older adults. Brain Behav Immun. (2012) 26:739-46. doi: 10.1016/j.bbi.2011.11.007
191. Kiecolt-Glaser JK, Wilson SJ. Psychiatric disorders, morbidity, and mortality: tracing mechanistic pathways to accelerated aging. Psychosom Med. (2016) 78:772-5. doi: 10.1097/PSY.0000000000000373
192. Bäckhed F, Fraser Claire M, Ringel Y, Sanders Mary E, Sartor RB, Sherman Philip M, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. (2012) 12:611-22. doi: 10.1016/j.chom.2012.10.012
193. Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. (2015) 26:26050. doi: 10.3402/mehd.v26.26050
194. Greenhalgh K, Meyer KM, Aagaard KM, Wilmes P. The human gut microbiome in health: establishment and resilience of microbiota over a lifetime. Environ Microbiol. (2016) 18:2103-16. doi: 10.1111/1462-2920.13318
195. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. (2012) 13:701-12. doi: 10.1038/nrn3346
196. Perez-Pardo P, Dodiya HB, Broersen LM, Douna H, van Wijk N, Lopes da Silva S, et al. Gut-brain and brain-gut axis in Parkinson's disease models: effects of a uridine and fish oil diet. Nutr Neurosci. (2017) 2017:1-12. doi: 10.1080/1028415X.2017.1294555
197. Jovel J, Patterson J, Wang W, Hotte N, O'Keefe S, Mitchel T, et al. Characterization of the gut microbiome using 16S or shotgun metagenomics. Front Microbiol. (2016) 7:459. doi: 10.3389/fmicb.2016.00459
198. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature (2014) 505:559-63. doi: 10.1038/nature12820
199. Davenport ER, Mizrahi-Man O, Michelini K, Barreiro LB, Ober C, Gilad Y. Seasonal variation in human gut microbiome composition. PLoS ONE (2014) 9:e90731. doi: 10.1371/journal.pone.0090731
200. Graf D, Di Cagno R, Fåk F, Flint HJ, Nyman M, Saarela M, et al. Contribution of diet to the composition of the human gut microbiota. Microb Ecol Health Dis. (2015) 26:26164. doi: 10.3402/mehd.v26.26164
201. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature (2011) 474:327-36. doi: 10.1038/nature10213
202. Dinan TG, Cryan JF. Brain-gut-microbiota axis and mental health. Psychosom Med. (2017) 79:920-6. doi: 10.1097/PSY.0000000000000519
203. Sherwin E, Dinan TG, Cryan JF. Recent developments in understanding the role of the gut microbiota in brain health and disease. Ann N Y Acad Sci. (2018) 1420:5-25. doi: 10.1111/nyas.13416
204. Spittaels H, Van Cauwenberghe E, Verbestel V, De Meester F, Van Dyck D, Verloigne M, et al. Objectively measured sedentary time and physical activity time across the lifespan: a cross-sectional study in four age groups. Int J Behav Nutr Phys Activ. (2012) 9:1. doi: 10.1186/1479-5868-9-149
205. Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U, et al. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet (2012) 380:247-57. doi: 10.1016/S0140-6736(12)60646-1
206. Gunter KB, Almstedt HC, Janz KF. Physical activity in childhood may be the key to optimizing lifespan skeletal health. Exerc Sport Sci Rev. (2012) 40:13. doi: 10.1097/JES.0b013e318236e5ee
207. Colman G, Dave D. Exercise, physical activity, and exertion over the business cycle. Soc Sci Med. (2013) 93:11-20. doi: 10.1016/j.socscimed.2013.05.032
208. Ng SW, Popkin BM. Time use and physical activity: a shift away from movement across the globe. Obesity Rev. (2012) 13:659-80. doi: 10.1111/j.1467-789X.2011.00982.x
209. Olza J, Calder PC. Metabolic and inflammatory responses to different caloric loads of a high-fat meal are distinct between normal-weight and obese individuals. J Nutr. (2014) 144:1493-4. doi: 10.3945/jn.114.199000
210. Hawley J, Holloszy J. Exercise: it's the real thing! Nutr Rev. (2009) 67:172-8. doi: 10.1111/j.1753-4887.2009.00185.x
211. Fuqua JS, Rogol AD. Neuroendocrine alterations in the exercising human: implications for energy homeostasis. Metabolism (2013) 62:911-21. doi: 10.1016/j.metabol.2013.01.016
212. Nielsen AR, Pedersen BK. The biological roles of exercise-induced cytokines: IL-6, IL-8, and IL-15. Appl Physiol Nutr Metab. (2007) 32:833-9. doi: 10.1139/H07-054
213. Pedersen BK, Fischer CP. Physiological roles of muscle-derived interleukin-6 in response to exercise. Curr Opin Clin Nutr Metab Care (2007) 10:265-71. doi: 10.1097/MCO.0b013e3280ebb5b3
214. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukocyte Biol. (2005) 78:819-35. doi: 10.1189/jlb.0505247
215. Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. Mediat Inflamm. (2008) 2008:109502. doi: 10.1155/2008/109502
216. Bermon S, Petriz B, Kajeniene A, Prestes J, Castell L, Franco OL. The microbiota: an exercise immunology perspective. Exerc Immunol Rev. (2015) 21:70-9
217. Campbell SC, Wisniewski PJ. Exercise is a novel promoter of intestinal health and microbial diversity. Exerc Sport Sci Rev. (2017) 45:41-7. doi: 10.1249/JES.0000000000000096
218. Jerath R, Barnes VA, Crawford MW. Mind-body response and neurophysiological changes during stress and meditation: central role of homeostasis. J Biol Regul Homeost Agents (2014) 28:545-54
219. Song C, Ikei H, Miyazaki Y. Physiological effects of nature therapy: a review of the research in Japan. Int J Environ Res Public Health. (2016) 13:781. doi: 10.3390/ijerph13080781
220. Endrighi R, Steptoe A, Hamer M. The effect of experimentally induced sedentariness on mood and psychobiological responses to mental stress. Br J Psychiatry (2016) 208:245-51. doi: 10.1192/bjp.bp.114.150755
221. Sallis JF, Owen N, Fisher EB. Ecological models of health behavior. In: Glanz K, Rimer BK, Viswanath K, editors. Health Behavior: Theory, Research, and Practice 5th ed. San Francisco, CA: Jossey-Bass (2015). p. 43-64
222. Aiello AE, Kaplan GA. Socioeconomic position and inflammatory and immune biomarkers of cardiovascular disease: applications to the panel study of income dynamics. Biodemogr Soc Biol. (2009) 55:178-205. doi: 10.1080/19485560903382304
223. Stowe R, Peek M, Perez N, Yetman D, Cutchin M, Goodwin J. Herpesvirus reactivation and socioeconomic position: a community-based study. J Epidemiol Commun Health (2010) 64:666. doi: 10.1136/jech.2008.078808
224. Fradkin C, Wallander JL, Elliott MN, Tortolero S, Cuccaro P, Schuster MA. Associations between socioeconomic status and obesity in diverse, young adolescents: variation across race/ethnicity and gender. Health Psychol. (2015) 34:1. doi: 10.1037/hea0000099
225. Reiss F. Socioeconomic inequalities and mental health problems in children and adolescents: a systematic review. Soc Sci Med. (2013) 90:24-31. doi: 10.1016/j.socscimed.2013.04.026
226. Mezuk B, Myers JM, Kendler KS. Integrating social science and behavioral genetics: testing the origin of socioeconomic disparities in depression using a genetically informed design. Am J Public Health. (2013) 103:S145-S51. doi: 10.2105/AJPH.2013.301247
227. Olshansky SJ, Antonucci T, Berkman L, Binstock RH, Boersch-Supan A, Cacioppo JT, et al. Differences in life expectancy due to race and educational differences are widening, and many may not catch up. Health Affairs (2012) 31:1803-13. doi: 10.1377/hlthaff.2011.0746
228. Cassel J. The contribution of the social environment to host resistance. Am J Epidemiol. (1976) 104:107-23. doi: 10.1093/oxfordjournals.aje.a112281
229. Berkman L, Syme L. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda county residents. Am J Epidemiol. (1979) 109:186-204. doi: 10.1093/oxfordjournals.aje.a112674
230. Ferrie J, Shipley M, Marmot M, Stansfeld S, Smith G. Health effects of anticipation of job change and non-employment: longitudinal data from the Whitehall II study. Br Med J. (1995) 311:1264-9. doi: 10.1136/bmj.311.7015.1264
231. Wallace R, Wallace B. Socioeconomic determinants of health: community marginalisation and the diffusion of disease and disorder in the United States. Br Med J. (1997) 314:1341-5. doi: 10.1136/bmj.314.7090.1341
232. Kennedy B, Kawachi I, Glass R, Prothrow-Stith D. Income distribution, socioeconomic status, and self rated health in the United States: multilevel analysis. Br Med J. (1998) 317:917-21. doi: 10.1136/bmj.317.7163.917
233. Kawachi I, Kennedy B. Income inequality and health: pathways and mechanisms. Health Serv Res. (1999) 34(1, Part II):215-27
234. Mackenbach J, Hawden-Chapman P. New perspectives on socioeconomic inequalities in health. Persp Biol Med. (2003) 46:428-44. doi: 10.1353/pbm.2003.0039
235. Marmot M. Social determinants of health inequities. Lancet (2005) 365:1099-104. doi: 10.1016/S0140-6736(05)74234-3
236. Marmot M. Achieving health equity: from root causes to fair outcomes. Lancet (2007) 370:1153-63. doi: 10.1016/S0140-6736(07)61385-3
237. Cohen S, Doyle WJ, Baum A. Socioeconomic status is associated with stress hormones. Psychosom Med. (2006) 68:414-20. doi: 10.1097/01.psy.0000221236.37158.b9
238. Stringhini S, Berkman L, Dugravot A, Ferrie JE, Marmot M, Kivimaki M, et al. Socioeconomic status, structural and functional measures of social support, and mortality The British Whitehall II cohort study, 1985-2009. Am J Epidemiol. (2012) 175:1275-83. doi: 10.1093/aje/kwr461
239. Troncone R, Discepolo V. Celiac disease and autoimmunity. J Pediatr Gastroenterol Nutr. (2014) 59:S9-S11. doi: 10.1097/01.mpg.0000450394.30780.ea
240. Reeves GEM. Coeliac disease: against the grain. Int Med J. (2004) 34:521-5. doi: 10.1111/j.1445-5994.2004.00691.x
241. Fisher BA, Bang S-Y, Chowdhury M, Lee H-S, Kim J-H, Charles P, et al. Smoking, the HLA-DRB1 shared epitope and ACPA fine-specificity in Koreans with rheumatoid arthritis: evidence for more than one pathogenic pathway linking smoking to disease. Ann Rheum Dis. (2014) 73:741-7. doi: 10.1136/annrheumdis-2012-202535
242. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut (2014) 63:1513-21. doi: 10.1136/gutjnl-2014-306928
243. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol. (2010) 6:339-46
244. You W-P, Henneberg M. Type 1 diabetes prevalence increasing globally and regionally: the role of natural selection and life expectancy at birth. BMJ Open Diab Res Care (2016) 4:1. doi: 10.1136/bmjdrc-2015-000161
245. Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis. (2015) 3:151-5. doi: 10.12691/ijcd-3-4-8
246. Cole SW. Human social genomics. PLoS Genet. (2014) 10:e1004601. doi: 10.1371/journal.pgen.1004601
247. Buric I, Farias M, Jong J, Mee C, Brazil IA. What is the molecular signature of mind-body interventions? A systematic review of gene expression changes induced by meditation and related practices. Front Immunol. (2017) 8:670. doi: 10.3389/fimmu.2017.00670
248. Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. (2013) 131:1288-96.e3. doi: 10.1016/j.jaci.2013.01.049
249. Olsen NJ, Schleich MA, Karp DR. Multifaceted effects of hydroxychloroquine in human disease. Semin Arthritis Rheum. (2013) 43:264-72. doi: 10.1016/j.semarthrit.2013.01.001
250. Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. J Hepatol. (2015) 62:S170-S85. doi: 10.1016/j.jhep.2015.02.042
251. Wolfe RM, Ang DC. Biologic therapies for autoimmune and connective tissue diseases. Immunol Allergy Clin. (2017) 37:283-99. doi: 10.1016/j.iac.2017.01.005
252. Sturmberg JP. Health System Redesign. How to Make Health Care Person-Centered, Equitable, and Sustainable. Cham: Springer (2018)
253. Sanderson I. Complexity,'practical rationality' and evidence-based policy making. Policy Politics (2006) 34:115-32. doi: 10.1332/030557306775212188
254. Sturmberg JP, O'Halloran DM, Martin CM. Health care reform-the need for a complex adaptive systems approach. In: Sturmberg JP, Martin CM, editors. Handbook of Systems and Complexity in Health. New York, NY: Springer (2013). p. 827-53
255. Wallace R, Wallace D. Structured psychosocial stress and therapeutic failure. J Biol Syst. (2004) 12:335-69. doi: 10.1142/S0218339004001129
256. Virchow R. Die medizinische Reform, 2. In: Sigerist HE, editor. Medicine and Human Welfare. New Haven, CT: Yale University Press (1941). p. 93
257. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci USA. (2012) 109:5995-9. doi: 10.1073/pnas.1118355109